We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.4B
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
+9.12%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.39B
AUM Growth
-$132M
(-2.4%)
Cap. Flow
-$296M
Cap. Flow
% of AUM
-5.49%
Top 10 Holdings %
Top 10 Hldgs %
30.62%
Holding
156
New
15
Increased
31
Reduced
31
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
THRD
Third Harmonic Bio
THRD
|
+$104M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$90.6M |
| 3 |
Thermo Fisher Scientific
TMO
|
+$49.7M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$47.8M |
| 5 |
BLU
BELLUS Health Inc.
BLU
|
+$33.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$168M |
| 2 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
+$151M |
| 3 |
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
|
+$108M |
| 4 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$81.3M |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$65.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.05% |
| 2 | Miscellaneous | 1.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
RxSight
RXST
$234M
| $14.4M | 0.27% |
1,202,833
-180,667
| -13% | -$2.48M |
|
|
JBIO
77
Jade Biosciences
JBIO
$1.11B
| $13.2M | 0.24% |
22,714
+9,040
| +66% | +$6.03M |
|
78
Passage Bio
PASG
$15.3M
| $11.2M | 0.21% |
446,600
| – | – |
|
79
Mirum Pharmaceuticals
MIRM
$6.1B
| $11M | 0.2% |
521,891
+242,391
| +87% | +$5.84M |
|
|
IMA
80
ImageneBio Inc
IMA
$55.8M
| $10.4M | 0.19% |
244,495
| – | – |
|
|
CINC
81
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| $10.3M | 0.19% |
+314,202
| New | +$8.88M |
|
82
Enliven Therapeutics
ELVN
$3.91B
| $10M | 0.19% |
1,096,642
| – | – |
|
|
FUSN
83
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $9.71M | 0.18% |
3,224,770
| – | – |
|
84
Disc Medicine
IRON
$2.58B
| $9.55M | 0.18% |
194,207
| – | – |
|
|
MREO
85
Mereo BioPharma
MREO
$45.5M
| $9.13M | 0.17% |
10,605,522
+8,004,054
| +308% | +$9.79M |
|
86
X4 Pharmaceuticals
XFOR
$359M
| $8.6M | 0.16% |
167,561
+121,766
| +266% | +$4.21M |
|
87
Cullinan Oncology
CGEM
$1.32B
| $8.17M | 0.15% |
637,287
-33,500
| -5% | -$451K |
|
88
Arcus Biosciences
RCUS
$3.1B
| $7.93M | 0.15% |
+303,000
| New | +$8.01M |
|
|
VTYX
89
DELISTED
Ventyx Biosciences
VTYX
| $7.86M | 0.15% |
225,000
-1,064,280
| -83% | -$23.6M |
|
|
DMRA
90
Damora Therapeutics
DMRA
$1.53B
| $7.73M | 0.14% |
163,637
| – | – |
|
91
EyePoint Inc
EYPT
$316M
| $7.68M | 0.14% |
970,860
+756,760
| +353% | +$7.03M |
|
92
NextCure
NXTC
$29.2M
| $7.46M | 0.14% |
225,918
| – | – |
|
93
Pulmonx
LUNG
$82M
| $7.25M | 0.13% |
435,000
| – | – |
|
|
JNCE
94
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $6.85M | 0.13% |
2,928,900
| – | – |
|
95
Oric Pharmaceuticals
ORIC
$1.28B
| $6.68M | 0.12% |
2,087,568
| – | – |
|
|
CMMB
96
Chemomab Therapeutics
CMMB
$18.1M
| $6.42M | 0.12% |
644,544
| – | – |
|
97
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| $6.06M | 0.11% |
76,400
-35,400
| -32% | -$2.98M |
|
98
CALL
Vaxcyte
PCVX
$8.81B
| $6M | 0.11% |
+250,000
| New | +$6.34M |
|
|
SYBX
99
DELISTED
Synlogic
SYBX
| $5.73M | 0.11% |
402,000
| – | – |
|
100
Corvus Pharmaceuticals
CRVS
$1.09B
| $5.68M | 0.11% |
6,943,654
| – | – |
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q3 2022 Portfolio in Review
As of Q3 2022, OrbiMed held 156 positions worth $5.39B, down 2.4% from $5.52B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
OrbiMed withdrew a net $296M in Q3 2022, closing 25 positions and reducing 31 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $168M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Miscellaneous.
Against the trend, OrbiMed opened a new position in Third Harmonic Bio worth $110M.
- OrbiMed's largest Q3 2022 buy was Third Harmonic Bio: 5,779,071 shares worth $110M.
- OrbiMed added most to Sarepta Therapeutics in Q3 2022, an estimated $90.6M increase.
- OrbiMed's biggest Q3 2022 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $81.3M.
- OrbiMed fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, selling an estimated $168M.
- OrbiMed's ten largest holdings make up 31% of its $5.39B portfolio in Q3 2022.
- OrbiMed opened 15 new positions and closed 25 in Q3 2022.
- OrbiMed's portfolio value fell 2.4% quarter-over-quarter to $5.39B.
Based on OrbiMed's 13F filing for Q3 2022, filed 14 Nov 2022.